Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 4
1995 4
1996 2
1997 3
1998 2
1999 1
2000 3
2001 2
2002 1
2003 2
2005 2
2006 3
2007 1
2008 2
2010 2
2011 4
2012 2
2014 1
2015 4
2016 6
2017 7
2018 10
2019 6
2020 4
2021 3
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Boukhaled GM, et al. Among authors: hirano n. Nat Immunol. 2022 Aug;23(8):1273-1283. doi: 10.1038/s41590-022-01262-7. Epub 2022 Jul 14. Nat Immunol. 2022. PMID: 35835962
[Development of universal CAR-T cells].
Kagoya Y, Hirano N. Kagoya Y, et al. Among authors: hirano n. Rinsho Ketsueki. 2022;63(7):782-789. doi: 10.11406/rinketsu.63.782. Rinsho Ketsueki. 2022. PMID: 35922948 Review. Japanese.
Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. Millar DG, et al. Among authors: hirano n. Cancer Immunol Immunother. 2023 Jul;72(7):2375-2392. doi: 10.1007/s00262-023-03413-7. Epub 2023 Mar 21. Cancer Immunol Immunother. 2023. PMID: 36943460 Free PMC article.
Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control.
Guo M, Abd-Rabbo D, Bertol B, Carew M, Lukhele S, Snell LM, Xu W, Boukhaled GM, Elsaesser H, Halaby MJ, Hirano N, McGaha TL, Brooks DG. Guo M, et al. Among authors: hirano n. bioRxiv [Preprint]. 2023 Apr 17:2023.04.15.536946. doi: 10.1101/2023.04.15.536946. bioRxiv. 2023. PMID: 37131587 Free PMC article. Updated. Preprint.
Adoptive T Cell Therapy Targeting CD1 and MR1.
Guo T, Chamoto K, Hirano N. Guo T, et al. Among authors: hirano n. Front Immunol. 2015 May 20;6:247. doi: 10.3389/fimmu.2015.00247. eCollection 2015. Front Immunol. 2015. PMID: 26052329 Free PMC article. Review.
Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response.
Kanwar N, Balde Z, Nair R, Dawe M, Chen S, Maganti M, Atenafu EG, Manolescu S, Wei C, Mao A, Fu F, Wang D, Cheung A, Yerofeyeva Y, Peters R, Liu K, Desmedt C, Sotiriou C, Szekely B, Kulka J, McKee TD, Hirano N, Bartlett JMS, Yaffe MJ, Bedard PL, McCready D, Done SJ. Kanwar N, et al. Among authors: hirano n. Cancer Res. 2021 Dec 15;81(24):6196-6206. doi: 10.1158/0008-5472.CAN-21-1079. Epub 2021 Oct 28. Cancer Res. 2021. PMID: 34711609 Free PMC article.
88 results